Aung M. Tun

Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Diego Villa et autres

us, ca (code pays fourni par la source)

Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study

Jeff P. Sharman, Aung M. Tun, José C. Villasboas, Ayed O. Ayed et autres

us, ch, ca (code pays fourni par la source)

Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma

José C. Villasboas, John M. Burke, Aung M. Tun, Steve Liu et autres

us (code pays fourni par la source)

The durability of consolidative transplant in mediastinal gray zone lymphoma, a single institution retrospective

Neda Amirmokhtari, Jianzheng Wu, Marc Hoffmann, Aung M. Tun et autres

gb (code pays fourni par la source)

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Aung M. Tun, Romil Patel, Frédérique St‐Pierre, Jenny Bhurtel et autres

us (code pays fourni par la source)

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel

Aung M. Tun, Matthew J. Frank, Madiha Iqbal, Alex F. Herrera et autres

us, nl, au (code pays fourni par la source)

Fixed-duration subcutaneous (SC) mosunetuzumab, with maintenance therapy, in patients (pts) with previously untreated high-tumor burden follicular lymphoma (HTB FL): Longer follow-up and exploratory circulating tumor (ct)DNA analysis of the Phase II MorningSun study

John M. Burke, Jeff P. Sharman, Bertrand Anz, Richard Zuniga et autres

us, gb, ch (code pays fourni par la source)

First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation

Christina Poh, Ryan C. Lynch, Craig H. Moskowitz, Michael A. Spinner et autres

us, Afrique du Sud, dk, es, gb, it (code pays fourni par la source)

IBCL-1494: MorningSun: Open-Label Phase 2 Trial of the Efficacy and Safety of Subcutaneous Mosunetuzumab as Frontline Treatment in Symptomatic Patients with Marginal Zone Lymphoma (MZL)

John M. Burke, Aung M. Tun, José C. Villasboas, Lihua E. Budde et autres

IBCL-341: Fixed-Duration Subcutaneous Mosunetuzumab in Patients With Previously Untreated High-Tumor Burden Follicular Lymphoma (FL): Interim Results From the Phase 2 MorningSun Study

Ian W. Flinn, John M. Burke, Jeff P. Sharman, Bertrand Anz et autres

us (code pays fourni par la source)

ORAL ABSTRACT: IBCL-1494 MorningSun: Open-Label Phase 2 Trial of the Efficacy and Safety of Subcutaneous Mosunetuzumab as Frontline Treatment in Symptomatic Patients with Marginal Zone Lymphoma (MZL)

John M. Burke, Aung M. Tun, Jose Villasboa, Lihua E. Budde et autres

POSTER: IBCL-1494 MorningSun: Open-Label Phase 2 Trial of the Efficacy and Safety of Subcutaneous Mosunetuzumab as Frontline Treatment in Symptomatic Patients with Marginal Zone Lymphoma (MZL)

John M. Burke, Aung M. Tun, José C. Villasboas, Lihua E. Budde et autres

us (code pays fourni par la source)